Pravastatin prolongs graft survival in an allogeneic rat model of orthotopic single lung transplantation

European Journal of Cardio-thoracic Surgery

Volumn 30, Issue 3, 2006, Pages 515-524

  Li, Yijiang ^a   Köster, Thorsten ^a   Mörike, Christiane ^a   v Hörsten, Stephan ^a   Martin, Ullrich ^a   Bader, Michael ^a   Haverich, Axel ^a   Simon, Andre R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Allogeneic; Immunosuppression; Lung transplantation; Rat; Rejection; Statin

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PRAVASTATIN; SODIUM CHLORIDE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT SURVIVAL; GRANULOCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOCHEMISTRY; HISTOLOGY; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; ORGAN DONOR; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ANTIGENS, CD4; BRONCHITIS; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; LUNG TRANSPLANTATION; MALE; MODELS, ANIMAL; PRAVASTATIN; RATS; RATS, INBRED F344; RATS, INBRED WKY; RECEPTORS, INTERLEUKIN-2; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 33746899669     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2006.03.072     Document Type: Article

References (22)

1. Moffatt S.D., Demers P., Robbins R.C., Doyle R., Wienacker A., Henig N., Theodore J., Reitz B.A., and Whyte R.I. Lung transplantation: a decade of experience. J Heart Lung Transplant 24 2 (2005) 145-151
2. Port F.K., Dykstra D.M., Merion R.M., and Wolfe R.A. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 5 4 Pt 2 (2005) 843-849
3. Studer S.M., Levy R.D., McNeil K., and Orens J.B. Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J 24 4 (2004) 674-685
4. Masterson R., Hewitson T., Leikis M., Walker R., Cohney S., and Becker G. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 80 3 (2005) 332-338
5. Crisby M. Modulation of the inflammatory process by statins. Timely Top Med Cardiovasc Dis 9 (2005) E3
6. McCarey D.W., Sattar N., and McInnes I.B. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?. Arthritis Res Ther 7 2 (2005) 55-61
7. Fehr T., Kahlert C., Fierz W., Joller-Jemelka H.I., Riesen W.F., Rickli H., Wuthrich R.P., and Ammann P. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 175 1 (2004) 83-90
8. Mach F. Statins as novel immunomodulators: from cell to potential clinical benefit. Thromb Haemost 90 4 (2003) 607-610
9. Raggatt L.J., and Partridge N.C. HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs 62 15 (2002) 2185-2191
10. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 6 12 (2000) 1399-1402
11. Steimle V., Siegrist C.A., Mottet A., Lisowska-Grospierre B., and Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265 5168 (1994) 106-109
12. Hillyard D.Z., Jardine A.G., McDonald K.J., and Cameron A.J. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis 172 2 (2004) 219-228
13. Siekmeier R., Gross W., and Marz W. Determination of pravastatin by high performance liquid chromatography. Int J Clin Pharmacol Ther 38 9 (2000) 419-425
14. Yousem S.A., Berry G.J., Cagle P.T., Chamberlain D., Husain A.N., Hruban R.H., Marchevsky A., Ohori N.P., Ritter J., Stewart S., and Tazelaar H.D. Revision of the 1990 Working Formulation for the Classification of Pulmonary Allograft Rejection: Lung Rejection Study Group. J Heart Lung Transplant 15 1 Pt 1 (1996) 1-15
15. Shingu K., Helfritz A., Kuhlmann S., Zielinska-Skowronek M., Jacobs R., Schmidt R.E., Pabst R., and von Horsten S. Kinetics of the early recruitment of leukocyte subsets at the sites of tumor cells in the lungs: natural killer (NK) cells rapidly attract monocytes but not lymphocytes in the surveillance of micrometastasis. Int J Cancer 99 1 (2002) 74-81
16. Wanner C., and Quaschning T. Abnormal lipid metabolism after renal transplantation. Ann Transplant 6 1 (2001) 5-8
17. Jacobsen W., Kirchner G., Hallensleben K., Mancinelli L., Deters M., Hackbarth I., Benet L.Z., Sewing K.F., and Christians U. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27 2 (1999) 173-179
18. Kocarek T.A., and Reddy A.B. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme a reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos 24 11 (1996) 1197-1204
19. Pierno S., De Luca A., Tricarico D., Roselli A., Natuzzi F., Ferrannini E., Laico M., and Camerino D.C. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther 275 3 (1995) 1490-1496
20. Sadeghi M.M., Tiglio A., Sadigh K., O'Donnell L., Collinge M., Pardi R., and Bender J.R. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71 9 (2001) 1262-1268
21. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin. Promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 6911 (2002) 78-84
22. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., and Archelos J.J. Statins As immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59 7 (2002) 990-997